Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.35 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.34 |
| ▸ | MMP1 | P03956 | 3/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2803839 | 0.92 | ALDH1A1 (0.39) | ALDH1A1KMT2AMEN1CYP1A2CYP2C9 | |
| SCHEMBL6423170 | 0.82 | ALDH1A1 (0.37) | ALDH1A1KMT2ACYP1A2CYP2C9EPHX2 | |
| SCHEMBL27750685 | 0.82 | ALDH1A1 (0.38) | ALDH1A1KMT2AMEN1TDP1 | |
| SCHEMBL2046623 | 0.78 | SLC6A4 (0.41) | KMT2AMEN1CYP1A2CYP2C9EPHX2 | |
| SCHEMBL6418597 | 0.77 | EPHX2 (0.35) | ALDH1A1CYP1A2CYP2C9EPHX2MMP1 | |
| SCHEMBL11484971 | 0.76 | HSD17B10 (0.52) | ALDH1A1KMT2AMEN1MMP1TDP1 | |
| SCHEMBL15624358 | 0.76 | KMT2A (0.55) | ALDH1A1KMT2AMEN1NPC1GAA | |
| SCHEMBL2048346 | 0.76 | ALDH1A1 (0.45) | ALDH1A1KMT2AMEN1GAATDP1 | |
| SCHEMBL2053130 | 0.76 | ALDH1A1 (0.38) | ALDH1A1KMT2AMEN1TDP1 | |
| SCHEMBL4638056 | 0.74 | EPHX2 (0.40) | CYP1A2CYP2C9EPHX2PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2329821-A1 | Treatment of ocular neovascular disorders such as macular degeneration, angiod streaks, uveitis and macular edema | GlaxoSmithKline LLC (US) | 2011-06-08 | — | — | EP | disclosed |